[cutting] ESG: Antibiotics on the agenda | IPE

Asset owners and asset managers who ignore the threat of anti-microbial resistance (AMR) to asset valuations do so at their peril— Abigail Herron, head of engagement, Aviva Investors

Source: www.ipe.com/investment/esg/esg-antibiotics-on-the-agenda/10017782.article


Note: Clear Profit wrote a piece on the topic last year, which can be found here.  ■